Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
MWN-AI** Summary
Standard BioTools Inc. (NASDAQ: LAB) announced significant product innovations in proteomics at the American Association for Cancer Research (AACR) Annual Meeting 2025, held on April 24, 2025. The unveiling includes the SomaScan™ Select 3.7K Assay, Single SOMAmer™ Reagents, and the cutting-edge CyTOF™ XT PRO system, each tailored to foster advancements in cancer research and drug development.
Michael Egholm, PhD, President and CEO, emphasized the company's commitment to delivering impactful solutions that bolster researchers' capabilities in translating complex biological data into therapeutics. The SomaScan Select 3.7K Assay stands out with its capacity to measure around 3,700 unique human proteins, covering 70% of FDA clinical biomarkers. This assay is particularly designed for researchers pursuing detailed insights in oncology and other areas, while also being compatible with diverse sample types.
Additionally, the Single SOMAmer Reagents serve as powerful alternatives to traditional antibodies, providing high sensitivity for detecting rare proteins with superior reproducibility. Meanwhile, the CyTOF XT PRO system enhances clinical trial efficiency by offering comprehensive immune profiling with the ability to analyze over 50 biomarkers rapidly.
At AACR 2025, Standard BioTools will showcase its innovations through 90 scientific presentations and posters, demonstrating the critical role of their proteomic technologies in biomarker discovery and patient stratification. A panel discussion titled “Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts” will feature esteemed experts and explore the future landscape of proteomics in clinical settings.
Standard BioTools continues to position itself as a leader in the field, aiming to bridge the gap between scientific research and effective health solutions. For more information, interested parties are invited to visit standardbio.com/aacr-2025.
MWN-AI** Analysis
Standard BioTools Inc. (NASDAQ: LAB) has made significant strides in proteomics with its recent product innovations unveiled at the AACR Annual Meeting 2025. As a financial analyst, I recommend closely monitoring LAB's performance and strategic positioning in the rapidly evolving life sciences market. The new offerings, including the SomaScan™ Select 3.7K Assay, Single SOMAmer™ Reagents, and the CyTOF™ XT PRO system, are poised to enhance research capabilities in oncology and other therapeutic areas, thereby potentially increasing demand for LAB’s products.
The SomaScan Select 3.7K Assay stands out due to its cost-effectiveness and versatility, providing researchers with access to a wide array of protein measurements that are crucial for clinical biomarker discovery. This positions LAB well within FDA-responsive markets, potentially attracting key contracts from research institutions and pharmaceutical developers focusing on oncology and immunology. The singleplex capability of SOMAmer™ Reagents also enhances LAB's value proposition by fostering high sensitivity in protein detection—essential for cutting-edge cancer research.
Additionally, the advancements in the CyTOF technology are likely to resonate well with clinical trial organizations aiming for more efficient drug development processes. With its ability to analyze over 50 biomarkers simultaneously, the CyTOF™ XT PRO system could become imperative for researchers needing timely and reliable patient response data.
As LAB enhances its portfolio with solutions that cater to critical translational research needs, it opens itself up to greater market share and revenue potential. However, investors should also be cognizant of the competition within the proteomics space and the pace of technological advancements. The upcoming panel discussion at AACR further underscores LAB's commitment to leadership in this field, and attendance at such events can provide invaluable insights into their strategic direction.
In summary, LAB presents a compelling investment opportunity characterized by innovative product offerings aimed at meeting the pressing needs in cancer research, warranting close attention from investors in the life sciences sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development
Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development
SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. These advancements – including the SomaScan™ Select 3.7K Assay, Single SOMAmer™ Reagents and the next-generation CyTOF™ XT PRO system – are purpose-built to support translational and clinical research across oncology and other therapeutic areas.
“At Standard BioTools, we are focused on delivering high-impact solutions that enable our customers to uncover novel biological insights and accelerate development of more effective therapeutics,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “The launches we’re announcing at AACR reflect our strategy to lead in proteomics by expanding our portfolio across consumables, instruments and services – helping researchers move faster, make smarter decisions and drive real impact in translational and clinical research.”
The SomaScan Platform: Next-generation assays and consumable reagents for translational research applications
SomaScan Select 3.7K Assay: a cost-effective, high-plex solution delivering approximately 3,700 unique human protein measurements. This targeted assay is designed for researchers seeking translational depth without full-plex cost while maintaining exceptional performance. Key highlights include:
- Covers 70% of FDA standard clinical biomarkers, making it a powerful tool for researchers investigating oncology, cardiometabolic disorders, immunology and other therapeutic areas
- Compatible with a variety of sample types, including human and non-human serum, plasma, cell lysates and tissue homogenates
- Offered through the Standard BioTools™ CAP/CLIA-accredited laboratory in Boulder, Colo.
Single SOMAmer Reagents: a powerful antibody alternative for affinity-based confirmatory methods (for example, ELISA, mass spectrometry pull-down assays) enabling singleplex protein measurement and low-abundance target detection. These new reagents offer:
- Access to approximately 11,000 unique, chemically synthesized, DNA-based reagents
- Superior reproducibility with low batch-to-batch variability
- High sensitivity with the capability of detecting rare proteins
CyTOF Technology: High-parameter immune profiling to accelerate clinical development
CyTOF XT PRO System: a next-generation platform designed to maximize clinical trial efficiency by delivering clearer, more complete and more reliable patient response data for drug development. Key enhancements include:
- The widest immune coverage, simultaneously analyzing 50-plus biomarkers for unparalleled understanding of drug mechanism and clinical response
- Streamlined workflow with up to 4x faster throughput, simplified sample prep and rapid panel design to accelerate research timelines from concept to insight in weeks
- New software that supports 21 CFR Part 11 compliance for clinical trial researchers
Standard BioTools at AACR
As part of its participation at AACR, Standard BioTools will host a panel discussion on Monday, April 28 from 12:30–1:30 pm in the Exhibitor Spotlight Theater . This panel will explore the future of proteomics and its critical role in translational research, biomarker discovery and clinical decision making.
Session title: Lost in Omics? Navigating the Path from Protein Discovery to Healthcare Impacts
Moderated by: Stephen Williams, MD, PhD – Chief Medical Officer, Standard BioTools
Featuring expert panelists:
- Elio Riboli, MD, MPH, HonFPH, FMedSci (Imperial College London)
- Brice Gaudilliere, MD, PhD (Stanford University)
- Wendy Fantl, PhD (Novartis)
- Michal Harel, PhD (OncoHost)
Standard BioTools and collaborators will present findings from key studies demonstrating the critical role proteomics plays in translational and clinical oncology research at AACR 2025, with 90 scientific posters and presentations powered by the Standard BioTools proteomic portfolio. These studies highlight the power of high-plex, single-cell and spatial proteomics in uncovering predictive biomarkers, elucidating mechanism of action and enabling patient stratification in cancer studies.
Standard BioTools invites AACR attendees to the highlighted poster and oral sessions, which can be found at: standardbio.com/aacr-2025 .
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB) has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook and LinkedIn.
For Research Use Only. Not for use in diagnostic procedures.
Patent and License Information: www.standardbio.com/legal/notices.
Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. All rights reserved.
Media contact
Emilia Costales
emilia.costales@standardbio.com
Investor contact
David Holmes
ir@standardbio.com
FAQ**
How does Standard BioTools Inc. LAB's new SomaScan Select 3.7K Assay enhance the ability of researchers to uncover novel biological insights in cancer research and other therapeutic areas?
In what ways does the CyTOF XT PRO system from Standard BioTools Inc. LAB streamline workflow and improve the efficiency of clinical trials for drug development?
Can you elaborate on the impact of the Single SOMAmer Reagents introduced by Standard BioTools Inc. LAB in terms of sensitivity and reproducibility for protein measurement?
What key findings on proteomics will be shared by Standard BioTools Inc. LAB's collaborators at the AACR 2025, and how do these findings address the challenges of biomarker discovery?
**MWN-AI FAQ is based on asking OpenAI questions about Standard BioTools Inc. (NASDAQ: LAB).
NASDAQ: LAB
LAB Trading
2.12% G/L:
$0.9534 Last:
723,321 Volume:
$0.9326 Open:
